Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Ambros Therapeutics
Acquired Company
Werewolf Therapeutics
IrvineBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Werewolf Therapeutics has filed for a merger with Ambros Therapeutics, valuing Ambros at USD 500 million. The merger agreement includes USD 150 million in financing and is subject to shareholder and Nasdaq approvals. Upon completion, the combined company is expected to be named Ambros Therapeutics.
Fundz sees it the moment Ambros Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Werewolf Therapeutics?
Werewolf Therapeutics was acquired by Ambros Therapeutics, based in Irvine. The deal was reported on October 16, 2026. Ambros Therapeutics is a biotech firm focused on developing a non-opioid pain medicine for Complex Regional Pain Syndrome type 1 (CRPS-1). Ambros Therapeutics is privately held and operates in Biotechnology.
When did Ambros Therapeutics acquire Werewolf Therapeutics?
Ambros Therapeutics's acquisition of Werewolf Therapeutics was reported on October 16, 2026. Werewolf Therapeutics has filed for a merger with Ambros Therapeutics, valuing Ambros at USD 500 million. The merger agreement includes USD 150 million in financing and is subject to shareholder and Nasdaq approvals. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Werewolf Therapeutics do?
Werewolf Therapeutics is a biotechnology firm specializing in immuno-oncology. The company is transitioning its focus toward late-stage rare-disease programs. It conducts research and development to create new therapeutic solutions. It is publicly traded (HOWL), operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.